Idorsia Presents Daridorexant Results in Children and Adolescents With Insomnia
Valid market news retained in the public archive without immediate LiveCast distribution.
Story updates
03:53:47 PM UTC
SquawkNews
Daridorexant, a dual orexin receptor antagonist, is the first investigational treatment in its class to demonstrate positive results in pediatric insomnia disorder, an area in which significant unmet needs remain for children and their families.A single 50 mg dose increased sleep time by 50 minutes…
03:54:20 PM UTC
SquawkNews
Idorsia reported a Phase 2 pediatric study where daridorexant 50 mg increased objective total sleep time by 50 minutes vs 20 with placebo after first dose, and 64 vs 27 minutes in those with neurodevelopmental disorders. Safety was similar to placebo; Phase 3 start is expected next year.Material De…